<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>James Routley | Feed</title>
    <link
      rel="stylesheet"
      type="text/css"
      href="../styles.css"
      media="screen"
    />
  </head>
  <body>
    <a href="/index.html">Back</a>
    <a href="https://www.jaist.ac.jp/english/whatsnew/press/2025/12/17-1.html">Original</a>
    <h1>Gut bacteria from amphibians and reptiles achieve tumor elimination in mice</h1>
    
    <div id="readability-page-1" class="page"><div id="main">
<p>Press Release</p>

<section>
<p><strong>【Key Research Achievements】</strong></p>
<ul>
<li>Demonstration that natural bacteria isolated from amphibian and reptile intestines achieve complete tumor elimination with single administration</li>
<li>Combines direct bacterial killing of cancer cells with immune system activation for comprehensive tumor destruction</li>
<li>Outperforms existing chemotherapy and immunotherapy with no adverse effects on normal tissues</li>
<li>Expected applications across diverse solid tumor types, opening new avenues for cancer treatment</li>
</ul>

<p><strong>【Research Overview】</strong></p>
<p>A research team of <a href="https://fp.jaist.ac.jp/public/Default2.aspx?id=711&amp;l=1" target="_blank" rel="noopener noreferrer">Prof. Eijiro Miyako</a> at the Japan Advanced Institute of Science and Technology (JAIST) has discovered that the bacterium <i>Ewingella americana</i>, isolated from the intestines of Japanese tree frogs (<i>Dryophytes japonicus</i>), possesses remarkably potent anticancer activity. This groundbreaking research has been published in the international journal <a href="https://doi.org/10.1080/19490976.2025.2599562" target="_blank" rel="noopener noreferrer"><strong>Gut Microbes</strong></a>.</p>

<p><strong>【Research Details】</strong></p>
<p><strong>Remarkable Therapeutic Efficacy</strong></p>
<p><img alt="pr20251215-11.png" src="https://www.jaist.ac.jp/whatsnew/images/pr20251215-11.png" width="375" height="256"/></p>
<p><strong>Figure 1.</strong> Anticancer efficacy: <i>Ewingella americana</i> versus conventional therapies. Tumor response: single i.v. dose of <i>E. americana</i> (200 µL, 5 × 10⁹ CFU/mL); four doses of doxorubicin or anti-PD-L1 (200 µL, 2.5 mg/kg per dose); PBS as control. Data: mean ± SEM (n = 5). ****, p &lt; 0.0001 (Student&#39;s two-sided t-test).</p>
<p><strong>Dual-Action Anticancer Mechanism</strong></p>
<p><i>E. americana</i> attacks cancer through two complementary mechanisms (<strong>Figure 2</strong>):</p>
<ol>
<li><strong>Direct Cytotoxic Effect</strong>: As a facultative anaerobic bacterium, <i>E. americana</i> selectively accumulates in the hypoxic tumor microenvironment and directly destroys cancer cells. Bacterial counts within tumors increase approximately 3,000-fold within 24 hours post-administration, efficiently attacking tumor tissue.</li>
<li><strong>Immune Activation Effect</strong>: The bacterial presence powerfully stimulates the immune system, recruiting T cells, B cells, and neutrophils to the tumor site. Pro-inflammatory cytokines (TNF-α, IFN-γ) produced by these immune cells further amplify immune responses and induce cancer cell apoptosis.</li>
</ol>
<p><img alt="pr20251215-12.png" src="https://www.jaist.ac.jp/whatsnew/images/pr20251215-12.png" width="100%"/></p>
<p><strong>Figure 2. </strong>Mechanisms underlying <i>Ewingella americana</i> antitumor effects.</p>

<p><strong>Tumor-Specific Accumulation Mechanism</strong></p>
<p><i>E. americana</i> selectively accumulates in tumor tissues with zero colonization in normal organs. This remarkable tumor specificity arises from multiple synergistic mechanisms:</p>
<ul>
<li><strong>Hypoxic Environment</strong>: The characteristic hypoxia of tumor tissues promotes anaerobic bacterial proliferation</li>
<li><strong>Immunosuppressive Environment</strong>: CD47 protein expressed by cancer cells creates local immunosuppression, forming a permissive niche for bacterial survival</li>
<li><strong>Abnormal Vascular Structure</strong>: Tumor vessels are leaky, facilitating bacterial extravasation</li>
<li><strong>Metabolic Abnormalities</strong>: Tumor-specific metabolites support selective bacterial growth</li>
</ul>
<p><strong>Excellent Safety Profile</strong></p>
<p>Comprehensive safety evaluation revealed that <i>E. americana</i> demonstrates:</p>
<ul>
<li>Rapid blood clearance (half-life ~1.2 hours, completely undetectable at 24 hours)</li>
<li>Zero bacterial colonization in normal organs including liver, spleen, lung, kidney, and heart</li>
<li>Only transient mild inflammatory responses, normalizing within 72 hours</li>
<li>No chronic toxicity during 60-day extended observation</li>
</ul>

<p><strong>【Future Directions】</strong></p>
<p>This research has established proof-of-concept for a novel cancer therapy using natural bacteria. Future research and development will focus on:</p>
<ol>
<li><strong>Expansion to Other Cancer Types</strong>: Efficacy validation in breast cancer, pancreatic cancer, melanoma, and other malignancies</li>
<li><strong>Optimization of Administration Methods</strong>: Development of safer and more effective delivery approaches including dose fractionation and intratumoral injection</li>
<li><strong>Combination Therapy Development</strong>: Investigation of synergistic effects with existing immunotherapy and chemotherapy</li>
</ol>
<p>This research demonstrates that unexplored biodiversity represents a treasure trove for novel medical technology development and holds promise for providing new therapeutic options for patients with refractory cancers.</p>

<p><strong>【Glossary】</strong></p>
<p><strong>Facultative Anaerobic Bacteria</strong>: Bacteria capable of growing in both oxygen-rich and oxygen-depleted environments, enabling selective proliferation in hypoxic tumor regions.</p>

<p><strong>【Publication Information】</strong></p>
<table>
<tbody>
<tr>
<td><strong>Title:</strong></td>
<td>Discovery and characterization of antitumor gut microbiota from amphibians and reptiles: <i>Ewingella americana</i> as a novel therapeutic agent with dual cytotoxic and immunomodulatory properties</td>
</tr>
<tr>
<td><strong>Authors:</strong></td>
<td>Seigo Iwata, Nagi Yamashita, Kensuke Asukabe, Matomo Sakari, Eijiro Miyako*</td>
</tr>
<tr>
<td><strong>Journal:</strong></td>
<td><i>Gut Microbes</i></td>
</tr>
<tr>
<td><strong>DOI:</strong></td>
<td><a href="https://doi.org/10.1080/19490976.2025.2599562" target="_blank" rel="noopener noreferrer">10.1080/19490976.2025.2599562</a></td>
</tr>
</tbody>
</table>
<p><strong>【Research Funding】</strong></p>
<p>This research was supported by:</p>
<ul>
<li>Japan Society for the Promotion of Science (JSPS) KAKENHI Grant-in-Aid for Scientific Research (A) (Grant No. 23H00551)</li>
<li>JSPS KAKENHI Grant-in-Aid for Challenging Research (Pioneering) (Grant No. 22K18440)</li>
<li>JSPS Program for Forming Japan&#39;s Peak Research Universities（J-PEAKS） (Grant No. JPJS00420230006)</li>
<li>Japan Science and Technology Agency (JST) Program for Co-creating Startup Ecosystem (Grant No. JPMJSF2318)</li>
<li>JST SPRING (Grant No. JPMJSP2102)</li>
</ul>
<p>December 15, 2025</p>
</section>
</div></div>
  </body>
</html>
